Faron Pharmaceuticals is a clinical-stage biopharmaceutical company based in Finland and the United States, with a focus on developing bexmarilimab, a first-in-class, humanized antibody that binds the Clever-1 target on myeloid cells and macrophages.

Clever-1 is an immunosuppressive receptor that promotes tumor growth and metastases when expressed on macrophages. Bexmarilimab primes the tumor microenvironment for optimal antitumor immune responses, in both hematological malignancies and solid tumors.